ACBP/DBI Neutralization Stimulates Anticancer Immune Responses By Upregulating Lamin A In T Cells
Our bodies possess intricate defense mechanisms against diseases, including cancer. Recent scientific investigations have highlighted a protein known as ACBP/DBI, which functions as a “stress hormone” within our tissues and can inhibit autophagy, a vital cellular process akin to the cell’s recycling system. Intriguingly, elevated levels of ACBP/DBI have been associated with a higher risk of cancer development.
Researchers have found that by blocking or “neutralizing” ACBP/DBI, the immune system’s capacity to combat cancer is significantly enhanced. This neutralization leads to a notable increase in a protein called Lamin A within T cells, which are specialized immune cells responsible for directly attacking cancerous cells. Lamin A is crucial for T cells to achieve optimal activation and effectively carry out their anti-cancer functions.
This heightened T cell activity results in improved control over tumor growth in various cancer models, including those for breast cancer, lung cancer, and sarcoma. These discoveries suggest that targeting ACBP/DBI could represent a promising new approach to enhance cancer treatments, potentially by making current immunotherapies more potent and offering a novel method to bolster the body’s inherent defenses against cancer.
Source: link to paper